RxDoctor Payments Data

Anum Gaffar, PA

Physician Assistant · Marietta, GANPI 1326657560

Payments from drug & device makers

$2,059in general payments, 2019–2025

Across 58 payments — averaging $35.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$431
  • Medtronic$385
  • Boston Scientific$184
  • Astellas Pharma US Inc$164
  • Myovant Sciences Inc.$130
  • Merck$126
  • plus $640 from 15 others

What the payments were for

  • Speaking & faculty fees$1196%
  • Food & beverage$1,77686%
  • Education$1648%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,059 in reported general payments places this provider in the 75th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$84,327
Medicare patients
559
Services billed
3,925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron108$87,052
GemtesaVibegron55$46,227
Trospium Chloride ErTrospium Chloride25$6,722
Tamsulosin Hcl384$5,184
Estradiol45$3,138
Testosterone23$2,877
Finasteride177$2,407
Potassium Citrate ErPotassium Citrate16$1,947
Methenamine Hippurate31$1,934
Trospium Chloride24$1,681
CefuroximeCefuroxime Axetil60$889
Alfuzosin Hcl ErAlfuzosin Hcl38$778
Dutasteride24$727
Testosterone Cypionate14$566
Oxybutynin Chloride ErOxybutynin Chloride34$489

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$164$87,052108 claims
Sumitomo Pharma America, Inc.Gemtesa$431$46,22755 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →